This study is for subjects that have been diagnosed with multiple myeloma. The investigational drug in this study is atezolizumab.The purpose of this study is to test the safety of various combinations of an experimental (not yet approved by the U.S. Food and Drug Administration [FDA] or any other regulatory authority outside the United States) drug called atezolizumab given with daratumumab, lenalidomide, and/or pomalidomide with or without dexamethasone (all approved by the FDA for the treatment of multiple myeloma) at different dose levels and to find out what effects, good or bad, the combination of these drugs has on you. Participants can expect to be in this study for 36 months.
This study is for adult patients who have high risk myeloma (MM), a cancer of the plasma cells that begins in their bone marro OR their MM returned after an autologous transplant. The study is being done to learn if maintenance treatment (chemotherapy) works better to control your disease than placebo.
This study is for patients that have been diagnosed with multiple myeloma. The investigational drug in this study is carfilzomib. The purpose of this study is to find out more about carfilzomib in people with multiple myeloma, a cancer that affects how normal blood cells grow and work. Participants can expect to be in this study for about 2.5 years (30 months), including a maximum of about 1.5 years (18 months) of study drug administration as well as about 1 year of follow-up visits.
The purpose of this study is to compare three different combinations of treatment plans to see whether one or more of them are better than a standard transplant procedure. The procedures being studied have the objective to reduce the occurrence of chronic GVHD.